Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis
- PMID: 1458072
- PMCID: PMC1883525
- DOI: 10.1136/bmj.305.6859.921
Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis
Abstract
Objectives: To compare the tolerance, efficacy, and pharmacokinetics of amphotericin deoxycholate (Fungizone) prepared in a parenteral fat emulsion (Intralipid 20%) or glucose in HIV patients with candidiasis.
Design: Non-blind randomised controlled trial.
Setting: University hospital; tertiary clinical care.
Patients: 22 HIV positive patients with oral candidiasis.
Interventions: Amphotericin 1 mg/kg/day given on four consecutive days as a one hour infusion dissolved in either 5% glucose (amphotericin-glucose) or parenteral fat emulsion at a final concentration of 2 g/l fat emulsion (amphotericin-fat emulsion).
Main outcome measures: Clinical tolerance (fever, chills, sweats, nausea, arterial pressure, and pulse rate); biological tolerance (serum creatinine, electrolyte, and magnesium values); clinical score of candidiasis; and serum concentrations of amphotericin.
Results: 11 patients were enrolled in each group. All the amphotericin-fat emulsion infusions were given without serious problem whereas four amphotericin-glucose infusions were stopped because of renal impairment (n = 3) or severe chills (n = 2), or both. For patients completing the amphotericin-glucose treatment creatine concentration increased by 42 mumol/l; four of seven patients had at least one creatinine value > or = 133 mumol/l versus one of 11 receiving amphotericin-fat emulsion. Magnesium concentration fell significantly with amphotericin-glucose but not with amphotericin-fat emulsion. Clinical side effects were noted in 36/38 infusions with amphotericin-glucose but 10/44 with amphotericin-fat emulsion. Oral candidiasis score was reduced similarly in both groups. Serum amphotericin concentrations were significantly lower and the volume of distribution of the drug higher after infusion of amphotericin-fat emulsion than after amphotericin-glucose.
Conclusions: Clinical and renal toxicity of amphotericin are reduced when the drug is prepared in fat emulsion. Preparation is simple and cost effective. Its efficacy is similar to that of conventional amphotericin.
Similar articles
-
Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis.Clin Infect Dis. 1996 Sep;23(3):556-62. doi: 10.1093/clinids/23.3.556. Clin Infect Dis. 1996. PMID: 8879780 Clinical Trial.
-
Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia.Ann Pharmacother. 1995 Dec;29(12):1197-201. doi: 10.1177/106002809502901201. Ann Pharmacother. 1995. PMID: 8672820 Clinical Trial.
-
Toxicity and efficacy of conventional amphotericin B deoxycholate versus escalating doses of amphotericin B deoxycholate---fat emulsion in HIV-infected patients with oral candidosis.Clin Microbiol Infect. 1997 Aug;3(4):455-461. doi: 10.1111/j.1469-0691.1997.tb00282.x. Clin Microbiol Infect. 1997. PMID: 11864156
-
What is the current and future status of conventional amphotericin B?Int J Antimicrob Agents. 2006 Jun;27 Suppl 1:12-6. doi: 10.1016/j.ijantimicag.2006.03.013. Epub 2006 May 16. Int J Antimicrob Agents. 2006. PMID: 16707251 Review.
-
Amphotericin B toxicity reduced by administration in fat emulsion.Ann Pharmacother. 1995 May;29(5):496-500. doi: 10.1177/106002809502900509. Ann Pharmacother. 1995. PMID: 7655134 Review.
Cited by
-
Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis.Antimicrob Agents Chemother. 2001 Feb;45(2):485-94. doi: 10.1128/AAC.45.2.485-494.2001. Antimicrob Agents Chemother. 2001. PMID: 11158745 Free PMC article.
-
Amphotericin B in lipid emulsion: stability, compatibility, and in vitro antifungal activity.Antimicrob Agents Chemother. 1998 Apr;42(4):762-6. doi: 10.1128/AAC.42.4.762. Antimicrob Agents Chemother. 1998. PMID: 9559779 Free PMC article.
-
Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study.BMJ. 1998 Aug 8;317(7155):379-84. doi: 10.1136/bmj.317.7155.379. BMJ. 1998. PMID: 9694753 Free PMC article. Clinical Trial.
-
Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients.Antimicrob Agents Chemother. 1999 Jun;43(6):1445-8. doi: 10.1128/AAC.43.6.1445. Antimicrob Agents Chemother. 1999. PMID: 10348768 Free PMC article. Clinical Trial.
-
Comparative Efficacy of Antifungal Agents Used in the Treatment of Oropharyngeal Candidiasis among HIV-Infected Adults: A Systematic Review and Network Meta-Analysis.J Fungi (Basel). 2021 Aug 5;7(8):637. doi: 10.3390/jof7080637. J Fungi (Basel). 2021. PMID: 34436176 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical